Vimarsana
Biggest News Aggregation in the World

Page 12 - Ioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ioscience Today - Breaking & Trending Today

Lexaria Bioscience Corp.: Lexaria Announces 2023 Annual Meeting Results - Vimarsana News

Lexaria Bioscience Corp.: Lexaria Announces 2023 Annual Meeting Results

KELOWNA, BC / ACCESSWIRE / May 10, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the 2023

Twist Bioscience Corporation: Twist Bioscience to Present at ITF World 2023 - Vimarsana News

Twist Bioscience Corporation: Twist Bioscience to Present at ITF World 2023

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust

Satellos Bioscience Inc. Announces Filing of Final Short Form Prospectus for Proposed Offering of Common Shares - Vimarsana News

Satellos Bioscience Inc. Announces Filing of Final Short Form Prospectus for Proposed Offering of Common Shares

Toronto, Ontario--(Newsfile Corp. - May 10, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the

Lexaria Bioscience Corp.: Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering - Vimarsana News

Lexaria Bioscience Corp.: Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering

KELOWNA, BC / ACCESSWIRE / May 8, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the pricing of

Lexaria Bioscience Corp.: Lexaria's Human Clinical Nicotine Study Completes Dosing as Planned - Vimarsana News

Lexaria Bioscience Corp.: Lexaria's Human Clinical Nicotine Study Completes Dosing as Planned

KELOWNA, BC / ACCESSWIRE / May 8, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that dosing of the targeted